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Introduction
Obstructive sleep apnea (OSA) is a relatively common sleep disorder, with a reported 
prevalence of 3–7% in the general population [1]. Intermittent hypoxia, a characteristic 
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feature of OSA [2], activates the hypoxia-inducible factor 1α (HIF-1α), a vascular 
endothelial growth factor (VEGF) regulator and promoter of angiogenesis. It has therefore 
become a topic of great interest in preclinical cancer research [3]. Recently, a link between 
OSA and increased cancer incidence [4], aggressiveness [5] and mortality [6] has been 
described. Biological mechanisms underlying these findings remain incompletely 
understood.
In a melanoma animal model, intermittent hypoxia was shown to be associated with higher 
tumor growth [7], metastatic rates [8] and plasma VEGF levels [9] compared to normoxic 
controls. It was postulated that the resulting hypoxic microenvironment might trigger 
adaptive cellular mechanisms that largely rely on the transcription of HIF-1α and its 
downregulated genes (VEGF, carbonic anhydrase-9 and glucose transporter-1).
Better understanding of the pathophysiology of clear cell RCC (ccRCC) in recent years has 
shown the important role of HIF-1α pathways [10,11], which has led to successful 
application of antiangiogenic drugs targeting VEGF [12] and has promoted the use of other 
related markers such as carbonic anhidrase-9 as prognostic markers [13]. Thus, HIF-1α and 
its downregulated genes have an important role in the pathophysiology of both OSA and 
ccRCC. Based on these data, a potential link between respiratory disease, hypoxia, and 
ccRCC is conceivable.
In the present study, we assessed whether patients with ccRCC and OSA had more 
aggressive disease by assessing the association between OSA and Fuhrman grade and tumor 
size, two clinical markers of tumor aggressiveness. We then attempted to determine whether 
OSA affected disease severity, metastasis-free survival (MFS) or cancer-specific survival 
(CSS).
Materials and Methods
After obtaining institutional review board approval, we identified 2,997 patients with ccRCC 
who underwent radical or partial nephrectomy, either at Memorial Sloan Kettering Cancer 
Center (MSKCC) between 1991 and 2014 (N= 2655) or at Hospital Clínic de Barcelona 
(HCB) between 1999 and 2012 (N= 342). Patients were excluded if they had metastasis at 
diagnosis (n=15) or were missing follow-up (n=7), American Society of Anesthesiologists 
(ASA) score (n=124) or Fuhrman grade (n=272). Our final cohort consisted of 2,579 
patients.
Baseline patient characteristics, including age, gender, body mass index (BMI), ASA score, 
history of smoking, and history of OSA, were collected from a prospectively maintained 
MSKCC database and a retrospective HCB database. Information on OSA was ascertained 
from a prior clinical diagnosis in the patient’s medical records.
Pathologic data included Fuhrman grade (defined as low [Grade 1 and 2], high [Grade 3 and 
4] and intermediate [those who had both Grade 2 and 3 in the pathology report]), tumor size, 
and stage according to the 2006 American Joint Committee on Cancer TNM classification 
system [14].
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To gain more insight into the biological significance of our results, we applied Gene Set 
Enrichment Analysis (GSEA) [15] from RNASeq data in 4 patients with OSA compared to 
120 without OSA, all of them from the MSKCC cohort profiled in the ccRCC Cancer 
Genome Atlas (TCGA) cohort [16]. All data were downloaded through the TCGA data 
portal (http://tcga-data.nci.nih.gov/tcga/findArchives.htm) and linked with patient 
characteristics. All gene sets (MSigDB) of size 15 to 500 genes (n = 5332 gene sets) were 
used in the GSEA. Student t test was used to quantify differential gene expression between 
the two groups. To account for gene–gene correlations in the enrichment analysis, gene set 
enrichment P values were computed with respect to a null distribution obtained from 1000 
randomizations of the patient phenotype labels.
Statistical analyses
Chi-square and Mann-Whitney U tests were used to compare baseline and pathologic 
variables between patients with and without OSA. Chi-square and linear regression were 
used to compare baseline characteristics between tumor grades. Univariate linear and 
logistic regression models were used to assess whether OSA was associated with tumor size 
or high Fuhrman grade. A non-parametric trend test was used to assess the association 
between OSA and Fuhrman grades from 1 to 4. To determine whether an association 
between OSA and disease aggressiveness was driven by behavioral habits/lifestyle factors, 
cellular changes due to hypoxia, or a combination of both factors, we created multivariable 
linear and logistic regression models. We assessed whether OSA was associated with tumor 
size or grade when controlling for factors known to be associated with RCC such as gender 
and age (per 10-yr increments) and factors we believed represented patient behaviors that 
may lead to diagnosis with more aggressive disease such as BMI (continuous), ASA score 
(I/II vs III/IV), and smoking history (yes/no).
In our cohort, only 69 patients were classified as having intermediate grade disease. Since 
there were so few patients in this group, we assessed both low and intermediate versus high 
grade, and low versus intermediate and high grade.
MFS and CSS estimate rates were calculated using the Kaplan-Meier method and compared 
using a log-rank test. To assess whether OSA was associated with survival through a 
pathway other than an association between OSA and more aggressive disease, we generated 
multivariable Cox regression models to test whether OSA was independently predictive of 
oncologic outcome when controlling for tumor size and Fuhrman grade. To test whether 
OSA is significantly associated with decreased MFS or CSS in intermediate/high grade 
patients only, an interaction term between Fuhrman grade and OSA was added in the Cox 
regression model. MFS was modeled for all patients in the cohort. CSS models were based 
on MSKCC patients only, since information on cause of death was not available for all 
patients from HCB. All analyses were performed using Stata 13 (StataCorp, College Station, 
TX, USA).
Results
Of 2,579 patients, 172 (7%) had OSA, which is in line with the self-reported prevalence of 
OSA in the general population [17]. They were more likely to be male and to have higher 
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BMI and ASA score (all p <0.0001) (Table 1). Furthermore, the distribution of Fuhrman 
grade categories was significantly different between patients with ccRCC who had OSA vs 
those who did not (p = 0.003). OSA was associated with high Fuhrman grade, with a risk 
difference of 13% (95% confidence interval [CI] 5%–20%). When including patients with 
intermediate Fuhrman grade in the high-grade group, the association was similar, with a risk 
difference of 11% (95% CI 3.4%–19%). However, OSA was not associated with either 
pathologic stage or tumor size (Table 1).
The covariates included in our multivariable model independently associated with Fuhrman 
grade were gender, age, smoking history, tumor size and ASA scores (Supplemental Table).
OSA was found to be predictive of both intermediate/high Fuhrman grade and high Fuhrman 
grade alone on univariate analysis (p = 0.004 and p = 0.001, respectively). When controlling 
for known risk factors and behavioral risk factors on multivariable analysis, the association 
between OSA and high Fuhrman grade remained significant (Table 2).
Consistent with these results, we found that the prevalence of OSA was significantly higher 
in patients with higher grade tumors. The rate of OSA was 4.9% in grade 1 patients, 5.6% in 
grade 2, 8.4% in grade 3, and 8.7% in grade 4 (non-parametric trend test, p=0.006).
We found no evidence that OSA was a significant predictor of tumor size on either 
univariate or multivariable analysis (p = 0.6 and p = 0.9, respectively).
We then compared survival outcomes of patients with ccRCC who had OSA with those who 
did not have OSA. Median follow-up among all survivors was 4.2 yr (interquartile range 
[IQR] 1.6–7.3). Overall, MFS and CSS estimates were not significantly different between 
the two groups (p = 0.4 and p = 0.5, respectively) (Supplemental Figures 1 and 2). Similarly, 
Cox regression models failed to show an association between OSA and MFS or CSS (p = 
0.5 and p = 0.4, respectively). Subsequently, we tested whether OSA was associated with 
poorer oncologic outcomes in intermediate/high-grade patients only, using an interaction 
term between Fuhrman grade and OSA in the multivariable Cox regression models, and 
found no evidence that OSA is associated with poorer MFS or CSS in this subgroup (p >0.9 
and p = 0.9, respectively).
The GSEA analysis to check for biological plausibility showed a trend (p=0.08) towards 
VEGF pathway enrichment in the OSA group (Supplemental Figure 3).
Discussion
Fuhrman grade is one of the most accepted prognostic factors in RCC [18]. Our results 
indicate that a history of OSA is associated with higher Fuhrman grade in patients with 
ccRCC. To our knowledge this is the first study assessing the association of OSA and 
adverse pathologic features of ccRCC.
The first indication that OSA may be associated with cancer has come from a multicenter 
study from Spain that suggested an increased incidence of colorectal, prostate, lung and 
breast cancer in patients with OSA [4]. Furthermore, cancer mortality has been correlated 
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with the severity of OSA in a large cohort study from Wisconsin [6]. Along these lines, an 
association between OSA and aggressive features of cancer has recently been postulated. 
Martínez-García et al. performed diagnostic sleep tests in 56 patients with cutaneous 
malignant melanoma in order to evaluate the association of dermatological and pathological 
features with sleep disorders [19]. This study found a higher incidence of OSA in the 
subgroup of patients with faster tumor growth rate. Importantly, the authors demonstrated a 
positive association between the severity of OSA defined by the apnea-hypopnea index and 
the nocturnal oxygen desaturation indexes (ODI3% and ODI4%) and markers of 
aggressiveness of malignant melanoma, namely the Breslow index, tumor growth rate and 
mitotic index. These results parallel our findings for ccRCC, supporting the notion that OSA 
may be a risk factor for the development of aggressive cancer phenotypes. We found that a 
significantly higher proportion of patients with OSA had high Fuhrman grade compared to 
patients without OSA. For the analyses of both intermediate and high-grade and high-grade 
alone, the magnitude of effect and confidence intervals were very similar. The more 
moderate effect seen on multivariable analysis was likely due to confounding between 
Fuhrman grade, OSA and the covariates included in the multivariable model. Patients with 
OSA were more likely to be male and more likely to have ASA scores of III or IV, while 
these characteristics were also associated with a higher likelihood of having a higher-grade 
tumor [20]. Since these two characteristics are associated with both OSA and grade, 
controlling for these factors and for lifestyle risk factors (BMI and smoking history) in our 
multivariable analysis, reduces the strength of the association between OSA and Fuhrman 
grade in both models. This indicates that while a patient’s health habits can be a risk factor 
for high-grade disease, there may also be an effect of OSA on Fuhrman grade that is 
unrelated to the correlation between OSA, obesity, and lifestyle risk factors.
On the other hand, we found no independent association between OSA and MFS or CSS. 
This could be due to the relatively low number of patients with OSA or low number of 
events (metastasis and death), so the statistical power of larger, prospective studies is 
required to more definitively test for an independent association between OSA and survival 
differences. Several hypotheses could influence these results. First, we should take into 
account the effect of behavioral confounders. OSA is associated with obesity, and obesity is 
often associated with other unhealthy habits (smoking, high sodium or high fat/cholesterol 
diets). Thus, these patients could potentially be less health-conscious and present later with 
more advanced disease, or less likely to follow up after surgery and therefore less likely to 
be diagnosed with metastases, which could explain why we see an association between OSA 
and grade but not between OSA and MFS. Another hypothesis is the ‘obesity paradox’ 
phenomenon described in ccRCC. This phenomenon means that obesity, a risk factor of 
kidney cancer, is paradoxically associated with longer survival rates [21]. Obesity is 
positively associated with OSA, and therefore, an interesting interaction between obesity, 
hypoxia and tumor behavior should be further explored.
Mouse models and in vitro studies provided experimental correlates to the potential role of 
OSA in malignant melanoma [7–9, 22]. Almendros et al. created a mouse model of sleep 
apnea by applying intermittent hypoxia to melanoma-injected mice, while a control group 
was submitted to normoxic air [7]. Intermittent hypoxia resulted in an almost two-fold 
increase in tumor weight after 14 days. Using the same model, the authors demonstrated in a 
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separate study that intermittent hypoxia caused a more than five-fold increase in the number 
of metastases per lung area after 30 days [8]. Recently, it has been hypothesized that tumor-
associated macrophages play a regulatory role on cancer cells under intermittent hypoxia 
[22] and sleep fragmentation [23].
Similarly, biologically plausible links between OSA, intermittent hypoxia and ccRCC exist. 
Under normal conditions, the Von Hippel-Lindau protein (VHL) acts as the substrate 
recognition protein of the E3 ubiquitin ligase complex, and induces the ubiquitination of the 
HIF-α subunit, leading to proteasomal degradation [24]. In ccRCC, VHL is downregulated, 
leading to HIF-α accumulation in the cell cytoplasm and translocation to the nucleus, where 
it activates the hypoxia adaptive response [25]. This pathway triggers the transcription of 
genes responsible for glycolysis and angiogenesis such as VEGF, thereby promoting tumor 
growth and survival [26]. Interestingly, the same adaptive response increasing HIF [27] and 
VEGF [28] levels has been described under conditions of intermittent hypoxia, leading to 
tumor growth and invasion potential [3]. In a subgroup of patients from our cohort we saw a 
trend towards VEGF pathway enrichment, although further research with larger patient 
samples is necessary.
While the present study is the first to investigate the relationship between OSA and 
aggressive features of ccRCC in a large cohort of patients, several limitations should be 
discussed. First, the presence of OSA was retrieved from prior clinical diagnosis. Despite the 
lack of a validated diagnostic tool, however, the prevalence of OSA in our cohort (7%) was 
in line with the self-reported prevalence of OSA in the general population [17]. A more 
accurate diagnosis of OSA would include information on its severity, time from diagnosis 
and treatment received. Observational studies with long-term follow-up find increased risk 
of all cause mortality compared to those with shorter follow-up. This may be explained by 
the accumulated effects of OSA [29, 30]. Although there is no evidence of the effect of 
treatment on cancer incidence, uncontrolled studies suggest that treatment with continuous 
positive airway pressure is able to reduce the number of cardiovascular events, including 
arrhythmias, myocardial infarction and stroke [30, 31].
Second, we included only patients undergoing partial or radical nephrectomy. While this 
design allowed the precise assessment of Fuhrman grade for all patients, it remains to be 
seen if our findings can be generalized to all patients with ccRCC. Although this type of 
cohort would include most of the patients diagnosed with localized ccRCC, it may be 
excluding patients with either advanced disease or low-risk disease that were not considered 
for surgery. Lastly, the assessment of Fuhrman grade suffers from inter and intraobserver 
variability and could have biased the results in a long-period study from different 
institutions.
Conclusions
In our study OSA was associated with higher Fuhrman grade in patients undergoing radical 
or partial nephrectomy for ccRCC. Our study offers a clinical correlate to experimental 
evidence highlighting hypoxia-related pathways in the pathogenesis of ccRCC. If validated 
in further prospective studies, our findings could help to stimulate future research in this 
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field that will help understanding etiological mechanisms and maybe delineate novel 
treatment targets for ccRCC.
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